2 completed. 2 Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 2 | Completed 2 |
Follow ceftolozane: new trials by email Literature Review of ceftolozane trials Research Report on ceftolozane
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Plasma Pharmacokinetics (PK) & Lung Penetration of Ceftolozane/Tazobactam in Participants With Pneumonia (MK-7625A-007) Ceftolozane/Tazobactam - Multiple Doses, Ceftolozane/Tazobactam - Single Dose - Critically Ill, Pneumonia | Phase 1 | Completed | Cubist Pharmaceuticals LLC, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA) | 37 | 2015-02-05 | 2019-08-28 |
| Pharmacokinetic and Safety Study of Ceftolozane/Tazobactam in Pediatric Participants Receiving Antibiotic Therapy for Proven or Suspected Gram-negative Infection or for Peri-operative Prophylaxis (MK-7625A-010) Ceftolozane/Tazobactam 1000/500 mg, Ceftolozane/Tazobactam 30/15 mg/kg, Ceftolozane/Tazobactam 20/10 mg/kg - Proven or Suspected Gram-negative Bacterial Infection, Peri-operative Prophylaxis | Phase 1 | Completed | Cubist Pharmaceuticals LLC, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA) | 43 | 2014-09-17 | 2019-09-11 |
Critical Illness (1) · Pneumonia (1)
Cubist Pharmaceuticals LLC, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA) (2)
PMID 30153232, PMID 32211756, PMID 33567333
2014 (1)